帕曲妥單抗

帕曲妥單抗（INN：Patritumab）是一種人單克隆抗體，設計用於治療非小細胞肺癌（英語：Non-small-cell lung cancer）。它充當免疫調節劑。^[1]^[2]

臨床試驗[編輯]

它正在進行針對頭頸部鱗狀細胞癌的二期臨床試驗。^[3]

它將被納入I-SPY 2乳腺癌試驗的新組中。^[4]

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 (PDF). WHO Drug Information. 2011, 25 (4).
^ Horinouchi H. The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy. December 2016, 16 (12): 1549–1555. PMID 27744717. S2CID 4035336. doi:10.1080/14712598.2016.1249846.
^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
^ Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer. October 2016.